JNJ
Pharmaceuticals and medical devices.
Price
…$156.22
+0.30% today
AI Outlook Score
76 / 100
Estimate, not a recommendation.
Analyst Consensus
Buy
Volatility
Calm — Low risk for beginners
Price trend · Johnson & Johnson
Educational only · Past performance does not guarantee future results.
AI-generated estimates only. Not financial advice. Market conditions can change and no outcome is guaranteed.
Growth
Moderate
Risk
Low
Stability
Stable
Momentum
Moderate
Beginner
Strong
Long-Term
Moderate
J&J develops prescription drugs and medical devices used in hospitals around the world. Long history of paying and raising its dividend.
Mixed exit signals
No urgent signals either way — a calm moment to reflect on your goals.
No major exit signals
Likely temporaryWhy: Current AI signals for Johnson & Johnson appear stable.
What changed: No meaningful change in volatility, outlook, or sentiment today.
When investors sometimes consider selling
Rebound potential analysis
Possible rebound factors — these are estimates, not guarantees.
Mixed rebound signals
There's no strong evidence of an imminent rebound or further decline — patience and observation may be warranted.
Rebound timing and magnitude are uncertain. Markets can stay weak longer than expected.
Estimate possible outcomes across different time horizons. AI-generated estimates only — actual market performance may vary significantly.
Investment amount
$500
After 6 mo
Conservative
$509.90
Expected
$519.62
Bullish
$536.19
After 1 yr
Conservative
$520.00
Expected
$540.00
Bullish
$575.00
After 3 yr
Conservative
$562.43
Expected
$629.86
Bullish
$760.44
After 5 yr
Conservative
$608.33
Expected
$734.66
Bullish
$1005.68
AI-generated estimates only. Not financial advice. Market conditions can change and no outcome is guaranteed.
About this AI estimate
Availability across popular investing platforms. Always confirm fees and limits in the app you choose.
Robinhood
Fidelity Investments
Fractional shares from $1
Charles Schwab
Stock Slices from $5
Webull
Educational availability info — not a recommendation of any broker.
Headlines are educational summaries — not investment advice.
Legal disclaimer